Bharat Biotech applies for emergency use authorisation for Covaxin

0
26

[ad_1]



After Pfizer and Serum Institute of India, now Hyderabad-based Bharat Biotech has applied for emergency use authorisation for their investigational vaccine candidate Covaxin to the Indian regulator on Monday.


The company is conducting a 26,000 subjects phase 3 efficacy trial in India to decide the efficacy of its candidate. This is without doubt one of the largest efficacy trials conducted in the country. The company has Phase 1 and phase 2 data in a position and would submit the interim data from large scale efficacy trials to the Drug Controller General of India (DCGI) for review.



Officials from the Central Drugs Standard Regulate Association (CDSCO), the Indian Council of Medical Research (ICMR) have been in steady touch with BBIL together with the expert committee on vaccine administration.

Dear Reader,

Commerce Standard has at all times strived tough to supply up-to-date information and observation on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and fixed feedback on how to enhance our offering have only made our unravel and commitment to these ideals stronger. Even right through these difficult times arising out of Covid-19, we continue to remain dedicated to keeping you informed and up to date with credible news, authoritative views and incisive observation on topical issues of relevance.

We, alternatively, have a request.

As we battle the economic affect of the pandemic, we need your enhance even more, in order that we will continue to provide you with more quality satisfied. Our subscription mannequin has seen an encouraging response from many of you, who have subscribed to our online satisfied. More subscription to our online satisfied can only help us achieve the goals of offering you even better and more applicable satisfied. We consider in free, reasonable and credible journalism. Your enhance through more subscriptions can help us practise the journalism to which we are dedicated.

Make stronger quality journalism and subscribe to Commerce Standard.

Digital Editor



First Published: Mon, December 07 2020. 21:57 IST

[ad_2]

Top stories / News / Commerce

LEAVE A REPLY

Please enter your comment!
Please enter your name here